Igor D Stolyarov

Learn More
OBJECTIVE To report the long-term safety and efficacy results from CAMMS223 comparing alemtuzumab with interferon β-1a in early, active relapsing-remitting multiple sclerosis (RRMS). What are the long-term effects of alemtuzumab treatment, received 36 to 48 months previously, on relapse and disability in early, active RRMS? This study provides evidence of(More)
The mechanism of the development of cognitive impairments in multiple sclerosis (MS) was investigated by studying glucose metabolism at the level of the brain by positron emission tomography (PET). A total of 61 patients with different types of MS were studied. Correlation analysis identified a relationship between cognitive impairments and regional glucose(More)
OBJECTIVE To investigate, in patients with Parkinson disease, the pharmacokinetics and pharmacodynamics of levodopa/carbidopa delivered via 3 different extended-release (ER) tablet formulations. METHODS This was a randomized, crossover study in patients with stable idiopathic Parkinson disease comparing a conventional ER tablet (C-ER) administered orally(More)
A total of 65 patients with clinically significant diagnoses of remitting multiple sclerosis in the stage of remission were studied. Neurological status was investigated with assessment on the FS and EDSS scales, with neuropsychological testing, and MRI scans (1.5 T). The severity of brain atrophy (in terms of the parenchyma volume) and the total volume of(More)
Neuropsychological studies were performed on 61 patients with the remitting (38 cases) and progressive (23 cases) types of multiple sclerosis (MS) to identify links between cognitive disorders with changes in the glucose metabolic rate (GMR) in the gray matter of the cerebral cortex in MS with different courses; neuroimaging was also performed. Correlation(More)
The article presents the literature data and results of our own researchon the use of positron emission tomography (PET) with different radiotracersin multiple sclerosis (MS). Informationon the operating principles of PET and PET studies with different radiotracers are considered. The results of PET studiesin different typesof MS, including determinationof(More)
Background: Delayed-release dimethyl fumarate (DMF), indicated for the treatment of patients with relapsing-remitting multiple sclerosis (MS), is a disease-modifying therapy with potential immunomodulatory and neuropro-tective effects. In clinical trials, DMF was associated with reduced white blood cell and absolute lymphocyte counts. Current US prescribing(More)
In this article, we discuss the aspects of neuroimmune interactions in various pathological processes, such as cerebral (including lateralized) ischemia (experimental and clinical data), the demyelinating process in the central nervous system (CNS) in patients with multiple sclerosis, and secondary immunodeficiency. The original and published data are(More)
Disease-modifying drugs (DMD) are currently used in the treatment of patients with multiple sclerosis (MS) in accordance with therapeutic standards, with the aim of decreasing the risk of developing exacerbations and thus reducing the rate of development of disability. However, the use of first-line substances is not successful in all cases. Second-line(More)